Skip to main content
Clinical Trials/NCT06121999
NCT06121999
Completed
Not Applicable

13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatosis (MASH) in Adults: A Randomized Control Trial

Grand Valley State University1 site in 1 country24 target enrollmentAugust 17, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Sponsor
Grand Valley State University
Enrollment
24
Locations
1
Primary Endpoint
The percentage of participants achieving a greater than or equal to 5% total body weight loss (TBWL).
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

The goal of this randomized control trial study is to compare an acceptance-based weight loss program with an occupational therapy behavioral lifestyle modification intervention in adults with metabolic associated-dysfunction steatotic liver disease (MASLD) and metabolic associated-dysfunction steatohepatitis (MASH). Formerly known as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The main questions the study aims to answer are:

  1. How do the two interventions compare for improving weight loss, health-related quality of life (HRQOL), and FibroScan results.
  2. Examine the role of occupational therapy on a multidisciplinary team for the treatment of MASLD and MASH.

Participants will meet with an occupational therapist for individual, 60-minute visits for 13 consecutive weeks. Each week participants will be weighed and then engage in a personalized intervention. At the end of the visit participants will be given worksheets and information to work on in-between visits.

Researchers will compare the intervention with an acceptance-based behavioral weight loss program that is commonly used for people with obesity and or type 2 diabetes.

Detailed Description

The research design is a pretest-posttest randomized control trial. Forty participants will be enrolled on a rolling bases and then assigned to one of two interventions. Occupational therapy with an acceptance-based behavioral weight loss program or only the acceptance-based behavioral weight loss program. Participants for both interventions will meet with an occupational therapist individually for 60 minutes for 13 consecutive weeks. Participants will be given modules from the weight loss program and worksheets to work on in-between sessions. Individuals in the occupational therapy intervention will also work on creating and individualized physical activity plan and implementation of the Mediterranean or Med Diet. At the beginning of each visit, participants will be weighed. During the visit their food logs and worksheets will be reviewed with the participant. Additional measurements during the 1st, 7th, and 13th visit include a liver FibroScan, waist measurement, and completion of questionnaires and assessments.

Registry
clinicaltrials.gov
Start Date
August 17, 2023
End Date
November 1, 2024
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Scott Truskowski

OST Department Chair, Associate Professor Occupational Science and Therapy Department

Grand Valley State University

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with NAFLD or NASH and have a body mass index greater than 25
  • Able to provide written and verbal consent to participate in the study
  • Live in the community and able their health status is such that they can be seen in the gastroenterology clinical practice
  • Must be patients of Gastroenterology Associates of Western Michigan.

Exclusion Criteria

  • diagnoses or the presence of other chronic liver and biliary diseases
  • enrolled in a clinical trial for NAFLD or NASH
  • Completed bariatric surgery less than 12-months prior to the start of the study
  • Achieved a 5% or greater total body weight loss within 6-months of the start of the study.
  • Presence of significant medical or psychiatric condition
  • \_ Presence of cognitive impairments that would inhibit participation in the study
  • Individuals who are nursing, pregnant, or planning on becoming pregnant during the study.
  • Individuals with a high likelihood of loss to follow-up

Outcomes

Primary Outcomes

The percentage of participants achieving a greater than or equal to 5% total body weight loss (TBWL).

Time Frame: End of study, week 13

The percentage of participants achieving a greater than or equal to 5% total body weight loss (TBWL) measures the proportion of participants who achieved the weight loss goal. Possible scores range from 1 - 100%, with higher scores indicating a better outcome.

The mean % of total body weight loss (%TBWL)

Time Frame: End of study, week 13

The mean % of total body weight loss (%TBWL) measures the average percentage of total body weight loss (%TBWL). Possible scores range from 1 to 15%, with higher scores indicating a better outcome.

Secondary Outcomes

  • Mean change in the kilopascals (kPa) and controlled attenuation pattern in decibels per meter (CAP dB/m) liver FibroScan scores(Baseline, week 1 compared to end of study, week 13)
  • Mean change in the Chronic Liver Disease Questionnaire - NAFLD/NASH (CLDQ-NAFLD/NASH)(Baseline, week 1 compared to end of study, week 13)

Study Sites (1)

Loading locations...

Similar Trials